ABSTRACT
However, visual field defects associated with glaucoma can continue to progress even after IOP is lowered to a specific target level [2] . Nearly, 40% of patients who have experienced a significant IOP reduction with PGA therapy require a further reduction and start to receive an additional topical ophthalmic medication [3, 4] . Combination regimens using multiple different ophthalmic solutions are less convenient for patients and increase their burden because patients need to take their prescribed ophthalmic solutions several times a day with a wait of at least 5 min between taking different solutions [5] [6] [7] . In contrast, fixed drugs of a PGA and a b-blocker produce a similar additive IOP-lowering effect without increasing the burden on patients and thus may be advantageous in preventing the risk of becoming non-adherent after the addition of a second drug [8] . Because visual field defects progress steadily even in normal tension glaucoma (NTG) [14] , a condition where IOP remains normal, NTG patients are also treated with PGA-based IOP-lowering therapy [15, 16] , and if visual field defects continue to progress despite a significant IOP reduction with initial monotherapy, a second drug is added [17] . Thus, these patients are also potential candidates to receive fixed drugs therapy. However, the efficacy of switching to a fixed drug therapy has not been extensively studied in this patient population. were included in the analysis. Baseline IOP was defined as the mean of two measurements obtained at two visits during PGA monotherapy. If both eyes were eligible for the study, the eye with a higher baseline IOP was chose or, if both eyes had an equal baseline IOP, the right eye was selected as the study eye.
Absolute and percent IOP reductions from baseline were analyzed for study eyes of patients who were followed up for at least 4 weeks after starting Duotrav therapy using repeated-measures analysis of variance and Steel's multiple comparison test. SPK and conjunctival hyperemia scores were analyzed by Steel's test. Missing values after 4 weeks were imputed using last observation carried forward method.
Adverse events for which a relationship to Duotrav could not be ruled out were graded according to the following criteria: mild (the patient recognized the adverse event but could tolerate the symptom), moderate (the patient found the symptom interfered with normal activities and was uncomfortable) and severe (the symptom was physically disabling and prevented the patient from working and normal activities). Eyelash changes, blepharal pigmentation and deepening of the eyelid sulcus were analyzed separately and cumulative incidence rates were calculated.
Overall incidence rate of adverse events was also calculated. Changes from baseline in blood pressure, pulse rate were analyzed using the Kruskal-Wallis test. Statistical analysis was performed by QOL RD Co., Ltd., and SOC Co., Ltd., using JMP Ò 9.0 and SAS Ò 9.3 (SAS Institute
Inc., Cary, NC, USA) with a two-sided significance level of 5%.
RESULTS
The study was conducted from Blepharal pigmentation was reported during the 4-week visit together with skin itching and Duotrav was discontinued at the patient's request. Eye pruritus and eye irritation occurred at 4 and 14 days of treatment, respectively, and increased blood pressure was noted during the 4-week visit together with mild rash. In these three cases, treatment was discontinued at the doctor's discretion and all the events improved or resolved during the study period. Among the mild events observed, increased blurred vision (occurring at 8 weeks in one patient) and deepening of the eyelid sulcus and blepharoptosis (occurring at 17 days in one patient) led to treatment discontinuation at the doctor's discretion (Table 4 ). All 157 eyes with at least 4 weeks of follow-up underwent serial examinations for eyelash changes, blepharal pigmentation, and deepening of the eyelid sulcus, where a change from baseline was considered an adverse event.
The cumulative incidence was highest for eyelash changes (42 patients; 26.8%), followed by blepharal pigmentation (29; 18.5%) and deepening of the eyelid sulcus (13; 8.3%; Table 5 ). 
DISCUSSION
In patients with POAG, NTG, or OH whose IOP had been lowered with PGA monotherapy but who were judged to require an additional ophthalmic medication, switching to travoprost/timolol maleate fixed combination (Duotrav) produced a further reduction in IOP after 12 weeks of treatment and was not associated with serious adverse events.
The goal of treating glaucoma is to maintain visual function. Currently, IOP-lowering therapy is the only evidence-based treatment and to prevent the progression of visual field defects, a greater IOP-lowering effect is needed [21, 22] . multiple drugs is indicated [3, 4] and in such cases, fixed drug may be more advantageous for continuous treatment as they cause less events that might lead to early discontinuation [5] [6] [7] . Although previous studies reported reductions in IOP after switching from PGA monotherapy to fixed drug containing the corresponding PGA, few studies have evaluated the efficacy of switching from any PGA monotherapy to a specific fixed drug. Among fixed drugs currently available, only Duotrav contains polyquaternium-1 (Polyquad) as a preservative instead of BAK and therefore patients are not exposed to the compound. These considerations led us to design a study to evaluate the efficacy and safety of switching to Duotrav in patients maintained on monotherapy with one of the four PGAs currently available in Japan (travoprost, latanoprost, tafluprost, and bimatoprost).
Baseline
In the present study, patients had a mean IOP of 16.3 ± 3.1 mmHg at baseline, which was calculated from measurements at two visits switching to Duotrav is similar to those reported previously in NTG populations [26, 27] . The absolute reduction of about 1.5 mmHg associated with switching to Duotrav seems to represent a meaningful treatment benefit, considering the findings from the Early
Manifest Glaucoma Trial where every 1 mmHg of IOP reduction has patient benefit [21] .
Because individual baseline IOP values
showed a wide variation, we assessed the treatment effect using baseline IOP values.
When study eyes were divided into three groups according to the baseline IOP Based on these results, the effects of Duotrav on the ocular surface were considered minimal in the present study population, including dry eyes. SPK has been reported at a higher frequency in patients using timolol ophthalmic solution [28, 29] and might be caused by the presence of BAK in the timolol solution [30, 31] . This preservative has strong antimicrobial activity but adversely affects the ocular surface [32, 33] . Adverse effects on the ocular surface may therefore be reduced by choosing a BAK-free regimen [20, 34] . Duotrav is a fixed-combination ophthalmic solution of travoprost and timolol and free of BAK, whereas combination regimens using separate ophthalmic solutions of travoprost and timolol or using other fixed drugs are associated with exposure to BAK because except for travoprost, they all contain BAK.
Duotrav contains polyquaternium-1 an alternative that is less toxic to the cornea than BAK [35] . There have been few studies on the effects of polyquaternium-1 in clinical practice but the present study suggests the advantage of using this compound as a preservative.
No serious adverse events were reported during Duotrav therapy but adverse events in six patients led to treatment discontinuation either at the patient's request or at the doctor's discretion, clearly suggesting that individual 
